Understanding Why Patients Stop or Continue Lung Cancer Treatment
Part of Cancer, Lungs & breathing clinical trials.
This research study asks lung cancer patients and their doctors about their experiences taking osimertinib (a targeted cancer medication) after surgery. Researchers want to understand what helps patients stay on this treatment and what makes it hard to continue, so they can better support patients in the future.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older with non-small cell lung cancer (NSCLC)
- You took osimertinib as a follow-up treatment after surgery to reduce cancer recurrence
- You either stopped osimertinib within the last 6 months, or you've been taking it for at least 34 months
- You can participate in an interview (online or in person) and allow it to be recorded
- You understand your own medical condition and can speak about your treatment experience
- You have not previously taken osimertinib or similar EGFR-inhibitor drugs as part of a research trial
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of the drug osimertinib with chemotherapy for people whose lung cancer has returned after they took osimertinib alone following surgery. It aims to see if this combined approach helps control the cancer better.
This trial collects data from people with early-stage lung cancer that has a common EGFR mutation. After complete surgical removal of the tumor, participants take osimertinib for 3 years and are followed regularly to see how well the treatment works and why resistance might develop.
This study looks at what doctors and patients consider when deciding on a first-line treatment for advanced lung cancer. It aims to understand how choices are made for people taking a type of targeted therapy.
This trial tests if removing the main lung tumor followed by the targeted therapy osimertinib helps people with advanced EGFR-mutant non-small cell lung cancer. It is for those who have not had prior treatment and are healthy enough for surgery.
This trial studies osimertinib in people with advanced or metastatic lung cancer that has specific EGFR gene changes. It aims to see how well this targeted medicine can control the cancer when surgery or radiotherapy won’t work.
This trial tests a targeted therapy pill (osimertinib) combined with radiation for people with a specific type of stage III lung cancer (EGFR mutation-positive) who cannot receive chemotherapy. The goal is to see if this treatment can shrink or control the cancer.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.